Pacira Pharmaceuticals ( (PCRX) ) has issued an announcement.
Pacira BioSciences reported a third-quarter net loss of $143.5 million, driven by a goodwill impairment, despite revenue growth to $168.6 million. The company continues to focus on non-opioid pain management, with products like EXPAREL and ZILRETTA contributing significantly to sales. CEO Frank D. Lee emphasized strategic investments for long-term growth, including the introduction of a new J-code for EXPAREL and the advancement of the PCRX-201 pipeline. Pacira’s financial guidance for 2024 remains unchanged, projecting total revenue of $680 million to $705 million.
For an in-depth examination of PCRX stock, go to TipRanks’ Stock Analysis page.
